Literature DB >> 12938163

Vitamin D and androgen regulation of prostatic growth.

Eddy S Leman1, Julie A Arlotti, Rajiv Dhir, Robert H Getzenberg.   

Abstract

Vitamin D has been reported to inhibit the growth of prostate cancer cells and model systems. In this study, we examined the interaction between 1,25-dihydroxyvitamin D(3) (1,25 D) in the presence or absence of endogenous testosterone on the growth and development of the adult rat prostate. Male Sprague-Dawley rats (165 days old) were either kept intact or castrated. Seven days after castration, the rats were treated with vehicle (control) or 1,25 D for 3 weeks and then sacrificed. Both ventral and dorsal lateral prostates were harvested; whole tissue lysates were collected and AR and VDR protein levels were analyzed by immunoblot analyses. Administration of 1,25 D in the intact animals decreased the prostatic size by 40%, compared to control animals, whereas 1,25 D did not influence the size of the prostate in castrated rats. 1,25 D administration in intact groups also increased both the AR and VDR protein levels by approximately twofold, whereas in castrated groups, 1,25 D only increased the AR protein level by 1.5-2.5-fold. 1,25 D in the presence of endogenous testosterone inhibits prostatic growth, whereas 1,25 D in the absence of endogenous testosterone does not affect prostatic growth. The growth inhibitory activity of 1,25 D in the presence of testosterone may be mediated through the ligand activated AR and VDR pathways. These studies may reveal important information about the potential efficacy of 1,25 D as well as hormonal status in understanding the development of prostate diseases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938163     DOI: 10.1002/jcb.10605

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status.

Authors:  Sarah Mordan-McCombs; Theodore Brown; Wei-Lin Winnie Wang; Ann-Christin Gaupel; Joellen Welsh; Martin Tenniswood
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-27       Impact factor: 4.292

2.  Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.

Authors:  Benjamin Mooso; Anisha Madhav; Sherra Johnson; Mohana Roy; Mary E Moore; Christabel Moy; Grace A Loredo; Rajendra G Mehta; Andrew T M Vaughan; Paramita M Ghosh
Journal:  Genes Cancer       Date:  2010-11-16

3.  Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Authors:  Jeannette M Schenk; Cathee A Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Kathleen C Torkko; Alan R Kristal; Ulrike Peters; Marian L Neuhouser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08       Impact factor: 4.254

Review 4.  Vitamin D, intermediary metabolism and prostate cancer tumor progression.

Authors:  Wei-Lin W Wang; Martin Tenniswood
Journal:  Front Physiol       Date:  2014-05-15       Impact factor: 4.566

5.  Gender, hyperandrogenism and vitamin D deficiency related functional and morphological alterations of rat cerebral arteries.

Authors:  Éva Pál; Leila Hadjadj; Zoltán Fontányi; Anna Monori-Kiss; Norbert Lippai; Eszter M Horváth; Attila Magyar; Eszter Horváth; Emil Monos; György L Nádasy; Zoltán Benyó; Szabolcs Várbíró
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

6.  Human male gamete endocrinology: 1alpha, 25-dihydroxyvitamin D3 (1,25(OH)2D3) regulates different aspects of human sperm biology and metabolism.

Authors:  Saveria Aquila; Carmela Guido; Emilia Middea; Ida Perrotta; Rosalinda Bruno; Michele Pellegrino; Sebastiano Andò
Journal:  Reprod Biol Endocrinol       Date:  2009-11-30       Impact factor: 5.211

7.  Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.

Authors:  Adebusola Alagbala Ajibade; Jason S Kirk; Ellen Karasik; Bryan Gillard; Michael T Moser; Candace S Johnson; Donald L Trump; Barbara A Foster
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.